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LETTER TO THE EDITOR

Silent Hypoxia in COVID-19:
What is Old is New Again!
Sir,
With Coronavirus disease of 2019 (COVID-19) pandemic, silent
hypoxemia (signiﬁcant hypoxemia without dyspnea) is a phenomenon to understand with associated shunt physiology,
preserved lung compliance, and lack of dead space.1 It applies
to any lung pathology which causes a reserved amount of shunt
while saving the rest of the lung such as lobar pneumonia or
atelectasis. Silent hypoxemia can last forever but individuals
could present to a healthcare facility with this condition occasionally. COVID-19 made us to think about this forgotten approach.
COVID-19 lung injury includes viral medial inﬂammation, alveolar epithelial dysfunction, impaired surfactant, alveolar
collapse, and increased pulmonary artery pressure patients.1,2
The disease process is been treated as acute respiratory
distress syndrome (ARDS) but it is not typical ARDS. With
normal lung compliance and many of them not in respiratory
distress, hypoxemia does not correlate with their clinical condition.1-2 Patients often presents in stable condition where they
are able to speak full sentences with oxygen saturation of 80%,
hence pulse oximetry may be a marker for respiratory dist1,2
ress.
Intra-pulmonary shunting, relatively preserved lung compliance, lack of excessive dead space, lack of substantial pulmonary
embolism or microvascular thrombosis and dysfunctional
1,2
hypoxemic vasoconstriction are the key features. COVID-19
patients faced slow onset severe hypoxemia with hypocapnia.
Atelectasis, obesity, elderly and underlying structural lung
disease could be the predisposing factors for rapid deterioration in the clinical condition.1,2 COVID-19 related hypoxemia is
diﬀerent as patient is not subjectively tachypneic but patterns
of respiration are making patients to have an enhanced respiratory drive and minute ventilation.1,2 In compensation, patients
have increased carbon dioxide (CO2) clearance which keeps
them away from getting short of breath.1,2

been seen in aviation science3,4; and COVID-19 made us to
rethink about this physiology. Firstly, with oxygenation, hypoxemia occurs when blood from right ventricle goes into left
ventricle without being oxygenated.1,2,5 It is due to ventilation
perfusion mismatch; hence, the net result is hypoxemia.
Increasing inhaled oxygen concentration can be used here.
Secondly there is the shunt physiology such anatomic abnormalities or dysfunctional parts of lung.1-4 Any patient with desaturation despite high supplemental oxygen likely has a shunt. CO2
clearance rely on amount of gas exchange with key reliance on
dead space such as scarred alveoli due to ARDS or in case pulmonary embolism where there is gas exchange but no CO2 clearance.1-3 Increasing dead space means patient must inhale more
gas to maintain the same CO2. Silent hypoxemia with normal
work of breathing occurs when there is right to left shunt, no
excessive dead space, normal lung compliance and lung resistance.3,4
Management of silent hypoxemia in COVID-19 does not require
intubation. Personal protection equipment should be the initial
consideration. Treatment options included high ﬂow nasal
cannula (HFNC) with surgical facemask over patient’s mouth,
awake-proning and repositioning (left lateral, sitting and right
lateral) to improve the saturation to 90%.3,4 Awake proning
showed feasibility in the times of scarce resources and shortage
of ventilators. Nasal cannula with oxygen saturation goal of
88-92% is been reported in the literature. Continuous positive
airway pressure therapy (CPAP) is another option before intubation. Airway pressure release ventilation (APRV), conventional
low tidal-volume ventilation, permissive hypercapnia and optimization of metabolic acid/base status and inhaled pulmonary
vasodilators are further treatment modalities.4,5
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Stages of silent hypoxia described as zones divided into subclinical, detection and high mortality.1,2 Subclinical zone is where
oxygen saturation is normal with normal respiratory rate. Detection zone is where there is gradual decline in oxygen saturation
with no subjective shortness of breath but respiratory rate
started to rise with progressive self-inﬂicted lung injury (SILI).
This is the zone for intervention; and dramatic results can be
seen if treatment is initiated.1,2 High mortality is the zone where
oxygen saturation drops with increasing subjective shortness of
breath. This is the zone where type H physiology transition with
1
respiratory failure can occur.
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